Clonality, the hallmark of cancer, was first documented in leukemia 37 years ago, based on the inactivation pattern of the X-linked G6PD gene (Fialkow et al., 1967) . Further documentation of leukemia as a stem cell disease come from studies identifying the Philadelphia chromosome in both myeloid and lymphoid cells from patients with chronic myelogenous leukemia (CML). The relatively recent availability of human HSC and progenitor cell from umbilical cord blood and peripheral blood progenitor cell apheresis collections has allowed several groups, including our own, to focus on using human hematopoietic stem, progenitor cells to study leukemia-associated fusion proteins. Although studies in NIH 3T3 cells or nonhematopoietic cell lines have yielded much information about the transforming activities of these proteins, in this review, we focus on the consequences of AML1-ETO in hematopoietic cells.
HSCs have the ability to self-renew and differentiate to all hematopoietic lineages, and by definition they are capable of repopulating a myeloablated host (Reya et al., 2001) ; this last requirement is demonstratable for murine but not human HSCs (for obvious reasons). Both symmetric and asymmetric cell divisions are required for the maintenance of HSCs and for their lifelong generation of progeny. Genes that control these processes are beginning to be identified (e.g. Hox B4 and sonic hedgehog) (Sauvageau et al., 1995; Bhardwaj et al., 2001) ; perturbation of their function is likely to be relevant to human leukemogenesis and to stem cell expansion.
Numerous assays have been developed to measure the earliest human HSCs, including the LTC-IC (long-term culture-initiating cell) assay, the cobblestone areaforming cell (CAFC) assay and the engraftment of normal human hematopoietic cells into immunodeficient mice (SRCs, or SCID repopulating cells). The NOD/ SCID mouse has been used to assay normal human HSCs and to identify the leukemic stem cell (Lapidot et al., 1994) . Such mouse models may be of value in develop our efforts to more effective treatment strategies for leukemia.
Accurate immunophenotyping of both human and murine stem cells has advanced considerably: The absence of lineage markers (LinÀ), the detectable expression of Sca-1 (a marker also found on mature lymphoid cells), low-level Thy1 expression and expression of c-kit (the receptor for stem cell factor) defines a group of murine stem cells (Uchida and Weissman, 1992) . Several distinct cell populations make up this collection of early cells (including short-and long-term repopulating cells), and numerous reviews describe the hierarchy of murine stem and progenitor cells (e.g. see Kondo et al., 2003) . The human stem cell is contained among cells that are CD34 þ , CD33À and CD38À. These cells express flt3 and VEGFR1 but not HLA-DR, and they lack lineage markers. Most human AMLs can engraft NOD/SCID mice; the engrafting cell is usually CD34 þ CD38À, but not in acute promyelocytic leukemia (AML, M3) where the NOD/SCID leukemia-initiating cell is CD34À and CD38 þ (Lapidot et al., 1994) . Following the identification of CD34À murine HSCs, it has been shown that CD34 expression can be modulated on transplantable HSCs. In addition, human CD34 gene expression appears to be regulated somewhat differently than murine CD34 expression.
AML1-ETO( þ ) AML
AML, M2 is a morphologically differentiated form of AML that frequently contains Auer rods and stains positively for myeloperoxidase. The t(8;21), which is usually found in the M2 subtype of AML, generates an invariant AML1-ETO transcript and protein, which consists of 177 amino acids of AML1 fused to 575 amino acids of ETO. Although other mRNA species have been identified in t(8;21) þ patients (de Greef et al., 1995) , that would generate truncated AML1-ETO proteins, it appears that these mRNAs coexist with mRNAs capable of producing full-length AML1-ETO protein. This aspect of t(8;21) AML has recently attracted further attention, based on the recent identification of a truncated AML1-ETO cDNA which appears to be leukemogenic on its own in mouse models .
AML1-ETO is generally expressed together with the wild-type AML1B (or AML 1c) protein, but dominant inhibitory effects of AML1-ETO have been found both in vitro (Frank et al., 1995; Meyers et al., 1995) and in vivo (Yergeau et al., 1997; Okuda et al., 1998) . t(8;21) þ AML is frequently associated with eosinophilia and a propensity to form granulocytic sarcomas, and it appears that the t(8;21) occurs in a stem cell with both myeloid and B-lymphoid capability (Miyamoto et al., 2000) . Accurate modeling of AML1-ETO( þ ) leukemia should help explain these properties.
Maintenance of stem cell phenotype during long-term culture
Knockin and transgenic (TG) murine models have been utilized to define the effects of AML1-ETO on murine HSCs. The initial attempts to model t(8;21) þ AML by knocking AML1-ETO into the AML1 locus were hampered by the occurrence of an embryonically lethal phenotype nearly identical to that seen in the AML1 (or CBFb) knockout mouse. AML1-ETO knockin mice die between day 12.5 and 13.5 dpc, with a lack of the fetal liver (definitive) hematopoiesis and an unusual pattern of CNS hemorrhage (Yergeau et al., 1997; Okuda et al., 1998) . Although the absence of definitive hematopoiesis precluded further study of AML1-ETO-related leukemogenesis, HSCs taken from the fetal liver of these mice show increased serial replating in culture and give rise to dysplastic monocytoid colonies in methylcellulose (Okuda et al., 1998) .
Both conventional and tetracycline (tet)-inducible TG approaches have been tried by the Zhang lab to study AML1-ETO; little in vivo phenotype was observed, although increased self-renewal was found in in vitro colony assays (Rhoades et al., 2000; Yuan et al., 2001) . In the studies by Rhoades et al., tet-induced expression of AML1-ETO caused the cells to undergo unlimited serial replating in culture, while removal of tet led to increased cell growth but loss of replating capability. Treatment of MRP8 AML1-ETO TG mice (which have no discernible hematopoietic phenotype) with ENU led to the development of AML (and ALL), with AML occurring in 45% of the mice (Yuan et al., 2001) . Conditional AML1-ETO knockin mice have been generated by Higuchi et al., which bypass the embryonic lethality of conventional AML1-ETO knockin mice (Higuchi et al., 2002) . These mice did not develop leukemia or abnormal peripheral blood counts. However, 31% of these mice developed granulocytic sarcomas or AML after ENU treatment (Higuchi et al., 2002) .
Studies using murine HSCs transduced with an AML1-ETO-expressing retrovirus, to rescue lethally irradiated mice, have confirmed the tendency of AML1-ETO"HSCs to favor self-renewal; 10 months post-transplant, the AML1-ETO mice have a 29-fold increase in HSCs and approximately 10% myeloblasts in the bone marrow (de Guzman et al., 2002) . This is consistent with an MDS phenotype.
A variety of studies suggest that important differences exist between murine and human cells in the pathways required for oncogenesis (Rangarajan and Weinberg, 2003) . Transformation by ras appears to differ in human vs murine cells (Hamad et al., 2002) , and murine telomeres are much longer than human telomeres. Also, unlike human cells, which must inactive both the p53 and pRb pathways to bypass telomere damage signaling pathways (Smogorzewska and de Lange, 2002) , murine cells require only p53 inactivation.
Human HSC studies
We have focused on defining the effects of AML1-ETO on CD34 þ human hematopoietic progenitor/stem cells. To accomplish this, we utilized an MSCV promoterdriven IRES-GFP retroviral construct to transduce human CD34 þ adult peripheral blood or cord blood progenitor cells. Introduction of AML1-ETO into human CD34 þ cells generated two distinct phenotypes: AML1-ETO expression inhibited the growth of committed progenitor cells, demonstrated in the CFU assay and in the first few weeks of the Delta culture. However, AML1-ETO promoted the growth of the more primitive HSCs, as measured by the CAFC stromal-based assay and by the increasing cell numbers in the late weeks of the Delta assay (Mulloy et al., 2002) . Morphologically these cells resemble myelodysplastic cells rather than acute leukemia.
More recently, we have shown that the introduction of AML1-ETO into normal CD34 þ adult PBPCs or cord blood routinely gives rise to the long-term cytokine-dependent growth in liquid culture of hematopoietic cells that maintain self-renewal and multilineage differentiation potential (Mulloy et al., 2003) . We have been able to maintain such cultures for up to B8 months, demonstrating a significant prolongation of human hematopoietic stem/progenitor cell longevity, while maintaining proliferative potential, cobblestone area-forming cell (CAFC) (and LTC-IC) activity, as well as continued CD34 expression. Although telomerase activity was preserved for many months, it declined near the end of the culture period, when rapid telomere shortening was observed.
Skewing of the AML1-ETO-transduced cells towards self-renewal is both highly reproducible and efficient. The cultures become clonal by approximately 6 weeks in culture. However, the lack of acquired karyotypic abnormalities suggests that the preservation of stem cell-like behavior is due to AML1-ETO expression. These cells engraft in NOD/SCID mice, but they do not cause leukemia. Their engraftment is not robust, likely due to their prolonged in vitro culturing (45 weeks) prior to being injected into the mice. It is known that such culturing can upregulate Fas expression and impair engraftment (Liu et al., 2003) . Engraftment of both myeloid and lymphoid cells in this model is interesting in view of the findings of Miyamoto et al., who showed that B cells, monocytes and stem cells from remission marrows of t(8;21) þ AML patients contain the AML1-ETO transcript (Miyamoto et al., 2000) .
Second hits
The presence of AML1-ETO mRNA in patients with long-term remission (Guerrasio et al., 1995) and in blood spots taken from identical twins (Wiemels et al., 2002) suggests that expression of AML1-ETO is not sufficient for inducing leukemia. This has led to a search for the relevant second (or third or fourth) hits, primarily focused on using mouse models. Other models are also being used including human and zebrafish, as expression of AML1-ETO in zebrafish leads to the abnormal proliferation of early, dysplastic appearing hematopoietic progenitor cells (Kalev-Zylinska et al., 2002) , and the zebrafish represents a powerful genetic system to search for second hits.
The t(8;21) can generate three potential 'hits'. It results in haploinsufficiency of AML1 and of ETO, and it generates the AML1-ETO fusion (but not an ETO-AML1 fusion.) It is important to point out that many models, including our own, do not precisely recreate this genetic background. Studies modeling APL, using crosses between the relevant transgenic mice and heterozygous gene targeted mice, suggest the importance of these gene dosage effects (Bernardi et al., 2002 ).
Murine models demonstrate that a constitutively activated tyrosine kinase and a CBF-related fusion transcription factor can cooperate in leukemogenesis. Although activated tyrosine kinases were initially found in myeloproliferative diseases, FLT3 activating mutations (most commonly an internal tandem repeat of a juxtamembrane portion of the receptor) are found in 20-30% of human AML samples. Such mutations occur most commonly in AML, M3, but they are also found in B9% of t(8;21) þ AML (Kottaridis et al., 2001) . Activating point mutations in the c-kit tyrosine kinase receptor have also been found in t(8;21) (and in inv(16) AML) (Care et al., 2003) and, less commonly, activating mutations in the M-CSF receptor (c-fms) or in the TrkA and TrkC receptors (which bind nerve growth factor and neurotrophin ligands, respectively) have been reported (Reuther et al., 2000; Abu-Duhier et al., 2003) . AML cells express IL-3 receptors and respond relatively uniquely to this cytokine for growth (Jordan et al., 2000) . The IL-3R consists of an alpha and common beta chain in man; the mouse has two alternative IL-3Ra chains. Mutations in the IL-3 receptor are not generally found in man, but an activated form of the IL-3Rb chain can promote the development of leukemia in the mouse (Phan et al., 2003) . Mutations in the GM-CSF receptor have not been reported in AML patients, whereas mutations in the G-CSF receptor (that truncate its intracellular tail) have been observed in AML and in particular, in children with severe congenital neutropenia who receive chronic, life-sustaining treatment with G-CSF. Such G-CSF receptor mutations have been shown to promote the development of leukemia in mouse models (Forbes et al., 2002) .
Modeling of these potentially cooperating events is underway, for example, the TEL-PDGFRb fusion tyrosine kinase has been shown to synergize with AML1-ETO in murine models of leukemia (Grisolano et al., 2003) . Mutations in or loss of expression of the genes encoding growth inhibitory signaling molecules have been found, involving the NF-1 gene (which leads to overactive ras signaling) or the ICSBP gene (which encodes a transcription factor involved in the growth inhibitory interferon signaling pathway). Lack of ICSBP results in a CML-like disorder in mice, but also cooperates with AML1-ETO to induce myeloblast proliferation (Schwieger et al., 2002) . Jun B null mice and CBP (but not p300) heterozygous mice also develop myeloproliferative syndromes (Kung et al., 2000; Passegue et al., 2001) . This suggests that decreased expression of these genes could also contribute to the development of acute leukemia.
Expression profiling of murine and human HSCs has only recently been reported, but such data will help us define the contribution of different signaling pathways to the self-renewal process and the differentiation potential of these cells. Similarly, broadly based DNA sequencing of specific genes in AML has begun to uncover certain patterns of mutations (Ley et al., 2003) . These patterns are particularly relevant because, although GATA-1 mutations are found in the AML, M7 seen in Down syndrome, they are not found in other AML, M7 patients (Wechsler et al., 2002) . The reason for this specificity is unclear, but is likely pathogenetically important.
Interference with transcription factors that regulate HSC differentiation or self-renewal
In addition to blocking AML1-dependent transcriptional activation, AML1-ETO can also block the activating effects of C/EBPa (a bZIP protein), ETS proteins such as PU.1 or MEF, and the Smad proteins involved in the TGFb response (Mao et al., 1999; Jakubowiak et al., 2000; Pabst et al., 2001a; Vangala et al., 2003) , via protein-protein interactions (see Table 1 ). C/EBPa plays an essential role in granulocytic differentiation, as mice lacking C/EBPa lack mature granulocytes. AML1-ETO downregulates C/EBPa levels and activity in t(8;21) þ AML, whereas AML, M2 cells that lack AML1-ETO often have point mutations in one C/EBPa allele, which create haploinsufficiency or dominant-negative forms of C/EBPa (Pabst et al., 2001b) . By blocking C/EBPa activity, AML1-ETO could impair granulocytic differentiation. MEF is a member of the ETS family of transcription factors that can regulate the cell cycle in HSCs and effect their accumulation (Lacorazza et al., 2002) . AML1-ETO binds MEF and inhibits its activity (Mao et al., 1999) . MEF (a.k.a. ELF4) is downregulated by AML1-ETO (Alcalay et al., 2003) and, in fact, MEF mRNA levels are lowest in t(8;21) and t(15;17) AMLs (Fukushima et al., 2003) .
AML1-ETO can also activate gene expression, including AP-1-dependent transcription in hematopoietic and nonhematopoietic cells Elsasser et al., 2003) , increased AP-1 activity can itself contribute to a decrease in C/EBPa activity in the cell. AML1-ETO can also block repression by PLZF (Melnick et al., 2000) , providing another explanation for the activation of gene expression by AML1-ETO. Furthermore, blockade of TGFb signals (Jakubowiak et al., 2000) and MIP1a expression (Bristow and Shore, 2003) by AML1-ETO can contribute to its proproliferative effects (see Table 2 ).
Transcript profiling of t(8;21) þ AML and other AML patient samples has also provided insight into the pathogenesis of AML1-ETO-associated leukemia. Table 3 shows target genes identified using subtractive (hybridization) techniques, microarray analysis or based on promoters studies demonstrating regulation by AML1-ETO. Examination of AML1-ETO target genes in leukemia cell lines, and in human CD34 þ HSCs, has identified several potential mediators of its effects on hematopoietic stem/progenitor cells. Among these genes are CDKN1A (upregulation), CEBPA (downregulation), NTRK1 (upregulation) (Cammenga et al., 2001) , and HCK (downregulation) variably reported by (Alcalay et al., 2003) . Studies are ongoing to further clarify the role of molecules identified by this methodology in AML1-ETO-related leukemogenesis. Interference with p53 signaling, by downregulating p19 ARF (Linggi et al., 2002) and increased ras signaling, by blocking NF-1 expression (Yang et al., 2003) may also contribute to this process. These genes were identified as AML1 or AML1-ETO targets, based on the presence of AML1 consensus binding sites [TG (T/C) GGT] in their promoters.
Two separate signals or not
As our understanding of how AML1-ETO affects stem cell behavior and what cooperative events are needed to generate AML improves, it is clear that AML1-ETO can impact multiple processes that lead to acute leukemia. The concepts of activated kinases driving proliferation in myeloproliferative disorders, and fusion transcription factors blocking differentiation in acute leukemia, have been very useful. However, crosstalk between these signals is likely pathogenetically important. Leukemic cell line experiments have demonstrated that AML1-ETO can block differentiation, yet in vitro (and in vivo) studies of both human and murine HSCs show that the block is incomplete. The findings generated by studies using leukemic cell lines may, at least in part, reflect selection for an observable phenotype, given that the cells are already leukemic. It may be more accurate to describe the effects of AML1-ETO (or other AML1 or CBFb fusion proteins) as delaying differentiation. 
TrkA ( These fusion proteins can delay cell cycle progression (Cao et al., 1997) , and because the readouts for these experiments are performed at specific time points, delayed differentiation can appear as blocked differentiation. It is unclear as to whether blocking differentiation at a stage where the cells have unlimited self-renewal, that is, at the stem cell stage, could be sufficient to generate leukemia. Although theoretically this may be true, it appears as though AML1-ETO( þ ) cells need additional proliferative signals. Such signals can come from an activated tyrosine kinase (e.g. c-kit or TEL-PDGFRB), but these two signals may not be independent. In fact, overexpressing an activated tyrosine kinase (e.g. FLT3 ITD) can interfere with differentiation (Chung KY et al., unpublished data), perhaps by preventing the cell from sufficiently arresting at G1 for differentiation to occur or by phosphorylating proteins like C/EBPa, thereby blocking their prodifferentiating activities (Zheng et al., 2003) . Likewise, fusion transcription factors like AML1-ETO or NUP98-HOXA9 (Chung KY et al., unpublished data) can provide self-renewal or proliferative signals in addition to partial interference with differentiation.
Summary
The t(8;21) translocation found in human AML can itself generate three 'hits', generating haploinsufficiency for both the AML1 gene and the ETO gene, as well as various gain-of-function properties inherent in AML1-ETO. Based on a variety of murine models, and our model of t(8;21) leukemia using human HSCs, it appears that the AML1-ETO fusion protein is not sufficient to cause leukemia, and that cooperating events are necessary (Rhoades et al., 2000; Yuan et al., 2001; de Guzman et al., 2002; Higuchi et al., 2002; Schwieger et al., 2002) . AML1-ETO promotes an increase in stem/early progenitors, perhaps by favoring self-renewal over differentiation (i.e. symmetric rather than asymmetric cell divisions), and this increases the pool of cells available for acquiring additional genetic (or epigenetic) events. Although activated tyrosine kinases have been found in AML1-ETO-expressing leukemia cells, and these lesions promote the growth of these cells in in vivo and in vitro models, most t(8;21) þ AMLs have not been shown to contain such identifiable activating mutations. Constitutive STAT activation is found in various AMLs in the absence of specific receptor activating mutations, suggesting that loss of suppression of cytokine signaling may also be involved in leukemogenesis. High-throughput analysis of human AML samples (both DNA sequencing and expression profiling using microarray technologies) will likely identify additional mutations in kinases or other signaling molecules that may then be implicated in cancer. Telomerase upregulation is likely another important aspect of human leukemogenesis.
Defining the mechanisms of transcriptional dysregulation in leukemia and the pathways activated by mutated kinases has already led to rational, clinical trials of targeted therapies. Histone deactylase inhibitors, DNA hypomethylating agents, farnesyltransferase inhibitors and tyrosine kinase inhibitors are currently being evaluated in clinical trials, whereas telomerase inhibitors are about to enter such trials. With further discovery, newer and hopefully more effective therapeutic approaches can be designed.
